Pancreatic cancer has a dismal prognosis and to date there are no targeted therapies for this malignancy. Using shotgun proteomics, the mRNA binding protein cold shock domain containing E1 (CSDE1), also called upstream-of-N-Ras, is detected in pancreatic cancer cell lines but not in normal pancreatic epithelial cells. The expression of CSDE1 in pancreatic cancer cells is confirmed by Western blotting and immunohistochemistry of human pancreatic tumors. In vitro functional assays show that siRNA downregulation of CSDE1 or gene knockout using CRISPR-Cas9 significantly reduce the invasiveness of pancreatic cancer cells. Together, this study reveals that CSDE1 is overexpressed in pancreatic cancer and is a potential therapeutic target to inhibit pancreatic cancer cell invasion.Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, with a 5-year survival rate of less than 9%. [1] To date, surgery is the only curative treatment for earlystage PDAC, but unfortunately, due to the lack of early symptoms and screening biomarkers, fewer than 20% of patients are candidates for surgery. [2] Chemotherapeutic drugs, such as gemcitabine, have been shown to only slightly improve patient survival and targeted therapies are missing. [2,3] Therefore, the design of targeted treatment is urgently needed in pancreatic cancer.The cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras was first documented in the 5ʹ flanking region of the NRAS gene. [4] CSDE1 is a member of the family of proteins